Synopsis
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
18
PharmaCompass offers a list of Ampicillin Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ampicillin Sodium manufacturer or Ampicillin Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ampicillin Sodium manufacturer or Ampicillin Sodium supplier.
A Ampiplus Simplex manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ampiplus Simplex, including repackagers and relabelers. The FDA regulates Ampiplus Simplex manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ampiplus Simplex API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ampiplus Simplex manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Ampiplus Simplex supplier is an individual or a company that provides Ampiplus Simplex active pharmaceutical ingredient (API) or Ampiplus Simplex finished formulations upon request. The Ampiplus Simplex suppliers may include Ampiplus Simplex API manufacturers, exporters, distributors and traders.
click here to find a list of Ampiplus Simplex suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Ampiplus Simplex DMF (Drug Master File) is a document detailing the whole manufacturing process of Ampiplus Simplex active pharmaceutical ingredient (API) in detail. Different forms of Ampiplus Simplex DMFs exist exist since differing nations have different regulations, such as Ampiplus Simplex USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ampiplus Simplex DMF submitted to regulatory agencies in the US is known as a USDMF. Ampiplus Simplex USDMF includes data on Ampiplus Simplex's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ampiplus Simplex USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ampiplus Simplex suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Ampiplus Simplex Drug Master File in Japan (Ampiplus Simplex JDMF) empowers Ampiplus Simplex API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Ampiplus Simplex JDMF during the approval evaluation for pharmaceutical products. At the time of Ampiplus Simplex JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Ampiplus Simplex suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Ampiplus Simplex Drug Master File in Korea (Ampiplus Simplex KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Ampiplus Simplex. The MFDS reviews the Ampiplus Simplex KDMF as part of the drug registration process and uses the information provided in the Ampiplus Simplex KDMF to evaluate the safety and efficacy of the drug.
After submitting a Ampiplus Simplex KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Ampiplus Simplex API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Ampiplus Simplex suppliers with KDMF on PharmaCompass.
A Ampiplus Simplex CEP of the European Pharmacopoeia monograph is often referred to as a Ampiplus Simplex Certificate of Suitability (COS). The purpose of a Ampiplus Simplex CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Ampiplus Simplex EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Ampiplus Simplex to their clients by showing that a Ampiplus Simplex CEP has been issued for it. The manufacturer submits a Ampiplus Simplex CEP (COS) as part of the market authorization procedure, and it takes on the role of a Ampiplus Simplex CEP holder for the record. Additionally, the data presented in the Ampiplus Simplex CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Ampiplus Simplex DMF.
A Ampiplus Simplex CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Ampiplus Simplex CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Ampiplus Simplex suppliers with CEP (COS) on PharmaCompass.
A Ampiplus Simplex written confirmation (Ampiplus Simplex WC) is an official document issued by a regulatory agency to a Ampiplus Simplex manufacturer, verifying that the manufacturing facility of a Ampiplus Simplex active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ampiplus Simplex APIs or Ampiplus Simplex finished pharmaceutical products to another nation, regulatory agencies frequently require a Ampiplus Simplex WC (written confirmation) as part of the regulatory process.
click here to find a list of Ampiplus Simplex suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ampiplus Simplex as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ampiplus Simplex API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ampiplus Simplex as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ampiplus Simplex and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ampiplus Simplex NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ampiplus Simplex suppliers with NDC on PharmaCompass.
Ampiplus Simplex Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ampiplus Simplex GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ampiplus Simplex GMP manufacturer or Ampiplus Simplex GMP API supplier for your needs.
A Ampiplus Simplex CoA (Certificate of Analysis) is a formal document that attests to Ampiplus Simplex's compliance with Ampiplus Simplex specifications and serves as a tool for batch-level quality control.
Ampiplus Simplex CoA mostly includes findings from lab analyses of a specific batch. For each Ampiplus Simplex CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ampiplus Simplex may be tested according to a variety of international standards, such as European Pharmacopoeia (Ampiplus Simplex EP), Ampiplus Simplex JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ampiplus Simplex USP).
